BioCentury
ARTICLE | Company News

NICE rebuffs Afinitor again

November 30, 2010 12:13 AM UTC

The U.K.'s NICE issued a second final appraisal determination (FAD) recommending against use of Afinitor everolimus from Novartis AG (NYSE:NVS; SIX:NOVN) for second-line treatment of advanced renal c...